Rein Therapeutics, Inc. (RNTX)
$0.00+$0.00 (+0.00%) Latest sessionExtended Hours
Latest RNTX Insider Trades
Rickenbach Josef H. vonOpen-market purchase$4K
Rickenbach Josef H. vonRickenbach Josef H. vonRickenbach Josef H. vonRickenbach Josef H. vonRein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
No Form 4 activity for RNTX in the last 90 days.
16 Form 4 filings on record, the earliest from Dec 4, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Rickenbach Josef H. von | Open-market purchase | Common stock , $0.001 par value | 3,420 | $1.04 | $4K | |
| Rickenbach Josef H. von | Open-market purchase | Common stock , $0.001 par value | 15,950 | $1.05 | $17K | |
| Rickenbach Josef H. von | Open-market purchase | Common stock , $0.001 par value | 23,190 | $1.06 | $24K | |
| Rickenbach Josef H. von | Open-market purchase | Common stock , $0.001 par value | 4,500 | $1.07 | $5K | |
| James Brian Windsor - Officer | Open-market purchase | Common stock , $0.001 par value | 25,000 | $1.00 | $25K | |
| James Brian Windsor - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Voss Capital, LP - 10% Owner | Open-market purchase | Common Stock, $0.001 par value | 104,183 | $1.22 | $128K | |
| Voss Capital, LP - 10% Owner | Open-market purchase | Common Stock, $0.001 par value | 178,392 | $1.39 | $248K | |
| Voss Capital, LP - 10% Owner | Open-market purchase | Common Stock, $0.001 par value | 30,176 | $1.39 | $42K | |
| Voss Capital, LP - 10% Owner | Open-market purchase | Common Stock, $0.001 par value | 92,642 | $1.37 | $127K | |
| Voss Capital, LP - 10% Owner | Open-market purchase | Common Stock, $0.001 par value | 4,840 | $1.37 | $7K | |
 Reinhard J. Ambros | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
| Rickenbach Josef H. von | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
 Alan A. Musso | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
 Manuel Aivado | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
| William Fairey | Grant or award | Stock Option (right to buy) | 17,500 | $0.00 | - | |
| James Brian Windsor - Officer | Open-market purchase | Common Stock | 239 | $2.24 | $535 | |
| James Brian Windsor - Officer | Open-market purchase | Common Stock | 161 | $2.25 | $362 | |
| Reinhard J. Ambros | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| William Fairey | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Manuel Aivado | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Alan A. Musso | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Rickenbach Josef H. von | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| James Brian Windsor - Officer | Grant or award | Stock Option (right to buy) | 517,500 | $0.00 | - |
Rein Therapeutics, Inc. (RNTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-29. The full record for RNTX runs to 16 Form 4 filings, the earliest from 2024-12-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RNTX were filed in the last 90 days. 12 purchases are on record for this company.
No insider sales of RNTX were filed in the last 90 days.
This page tracks RNTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RNTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
